FDA's off-label guidance may be up for review

Share this article:
The Obama administration will review and may change an FDA guidance on off-label marketing that was approved in the waning days of the Bush administration, according to McClatchy Newspapers. The news group quoted Sen. Chuck Grassley (R-IA), a frequent FDA critic, as saying that a “legislative fix may be in order.” Grassley had said he had serious concerns about a guidance that would deem as appropriate something that “FDA once considered evidence of unlawful marketing.”

The new policy was disclosed in a Jan. 12 final guidance for industry that skipped the customary “draft” document stage for the gathering of comments. The document was issued not by the FDA's drug or medical device centers which would normally handle such matters, but by the politicized Office of the Commissioner.
Previous agency policy had for many years disfavored dissemination of unapproved use info by drug companies, but the agency was forced by congressional and court intervention to tolerate it under provisions that expired in 2006. 
Share this article:
You must be a registered member of MMM to post a comment.

Reimagining healthcare? We want to hear about it.
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters


More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

Upward Move: Jose Rivera

Upward Move: Jose Rivera

Jose Rivera. EVP, account director, Concentric